GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Results of Operations and Financial Condition

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Results of Operations and Financial Condition
Item 9.01 Results of Operations and Financial Condition.

Story continues below

On March 15, 2019, Gemphire Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2018.The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished to Item 9.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01

Financial Statements and Exhibits.

Gemphire Therapeutics Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Gemp_8-K_Ex. 99.1 Exhibit 99.1   Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results   LIVONIA,…
To view the full exhibit click here


Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

An ad to help with our costs